Self-Expanding Valve in Extreme Surgical Risk After 5 Years

Patients with aortic stenosis and extreme surgical risk have extremely high mortality due to known comorbidities. The short-term benefit of transcatheter aortic valve replacement (TAVR) with self-expanding valve is clear, and it warrants the procedure in this challenging population.

Post-dilatación de válvulas autoexpandibles

While elderly patients with comorbidities who are at extreme surgical risk might be eligible for TAVR, the futility risk is always present.

The CoreValve US Extreme Risk Pivotal study, published in Circulation, presents the 5-year clinical and echocardiographic outcomes in this extreme-risk population treated with the CoreValve self-expanding supra-annular valve.

The primary endpoint of the study was all-cause death or disabling stroke. Secondary endpoints included echocardiographic parameters and quality of life.

About 639 patients at extreme surgical risk (mean age: 82.8 ± 8.4; mean Society of Thoracic Surgeons Predicted Risk of Mortality: 10.4 ± 5.6%) between 2011 and 2012 were prospectively included.

At 5 years, mortality or disabling stroke rate was extremely high, at 72.6%—though such figure should be interpreted in the context of the intrinsic risk of this population. Transfemoral access was selected in 77% of cases, and no difference was observed with other accesses (which was the case in other series). 


Read also: Which Type 2 Endoleaks Should We Intervene?


As regards the lucky surviving patients at 5 years of follow-up who were able to undergo an echocardiogram, the mean transvalvular gradient was 7.5 ± 5.9 mmHg, and 3.1% had moderate/severe valve regurgitation. This shows the valve has a good long-term hemodynamic performance.

One month after the procedure, quality of life improved significantly from baseline; however, after a year, it continually and gradually declined. Despite this gradual decline, quality of life at 5 years was still significantly better than at baseline.

Conclusion

Patients with severe aortic stenosis and extreme surgical risk who undergo TAVR with a self-expanding valve have high 5-year mortality rates. However, the huge short-term benefit coupled with a persistent improvement in quality of life at 5 years among survivors clearly justifies the procedure.

Original Title: Five-Year Clinical and Quality of Life Outcomes From the CoreValve US Pivotal Extreme Risk Trial.

Reference: Suzanne V. Arnold et al. Circ Cardiovasc Interv. 2021 Jun;14(6):e010258. doi: 10.1161/CIRCINTERVENTIONS.120.010258.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

SMART-CHOICE 3 | Efficacy and Safety of Clopidogrel vs Aspirin Monotherapy in High Risk Patients after Percutaneous Coronary Intervention

Courtesy of Dr. Juan Manuel Pérez. After post percutaneous coronary intervention (PCI) standard duration dual antiplatelet therapy (DAPT), the optimal long term monotherapy strategy is...

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...